| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Poly (I:C):Kanamycin (1:1) targets TLR3 and RIG-I-like receptors through its poly(I:C) component, and the 70S bacterial ribosome through its kanamycin component. Poly(I:C) is a synthetic dsRNA analog and a TLR3 receptor agonist. Kanamycin is an antibiotic that binds to the 70S ribosomal subunit, inhibiting protein synthesis.
|
|---|---|
| ln Vitro |
In vitro, Poly (I:C) acts as a TLR3 receptor agonist, inducing the production of interferons and pro-inflammatory cytokines. This compound can be used in cell culture to simulate viral infection. Kanamycin is an antibacterial agent active against both Gram-negative and Gram-positive bacteria. The 1:1 combination is often used in cell culture to study immune responses.
|
| ln Vivo |
In vivo, Poly (I:C) can be used as a vaccine adjuvant to enhance innate and adaptive immune responses. It can also be used to induce apoptosis in cancer cells. The kanamycin component is used to treat bacterial infections. The combination is useful for studying immune modulation and antimicrobial therapy in animal models.
|
| Enzyme Assay |
A cell-free TLR3 binding assay for the poly(I:C) component can be performed using a TR-FRET assay or SPR with purified TLR3 protein. For kanamycin, a cell-free binding assay would measure its binding to the bacterial 70S ribosomal subunit or purified ribosomal RNA using SPR or a filter-binding assay to determine its affinity and specificity.
|
| Cell Assay |
HEK293 cells stably expressing human TLR3 are seeded in 96-well plates. Cells are treated with Poly (I:C):Kanamycin (1:1) (0.1-100 ug/mL) for 6-24 hours. Supernatants are collected, and IFN-beta and other cytokine levels are measured by ELISA. This confirms activation of the TLR3 pathway. For antibacterial assays, bacteria are grown in broth with the compound, and the MIC is determined.
|
| Animal Protocol |
A standard in vivo protocol would involve using Poly (I:C):Kanamycin (1:1) as a vaccine adjuvant in a mouse model. Female BALB/c mice are vaccinated with an antigen mixed with the compound. Mice are then challenged with a pathogen. Immune responses are evaluated by measuring antibody titers (ELISA) and T cell responses (ELISpot). Tumor growth inhibition can be assessed in cancer models.
|
| ADME/Pharmacokinetics |
Poly(I:C) has a very short plasma half-life (minutes) due to rapid degradation by serum nucleases. Kanamycin is poorly absorbed orally and has a plasma half-life of 2-3 hours in humans. The complex is designed for local or injectable administration. Specific PK data for the 1:1 mixture are not available.
|
| Toxicity/Toxicokinetics |
Poly(I:C) can cause significant inflammatory responses and cytokine storm at high doses. Kanamycin is associated with nephrotoxicity and ototoxicity. The complex is expected to have similar safety concerns. It should be used with appropriate caution in vivo. Standard safety precautions for handling RNA and antibiotics should be followed.
|
| References | |
| Additional Infomation |
Poly (I:C):Kanamycin (1:1) is a research-grade complex and is not an approved drug. It is a mixture of poly (I:C) and kanamycin. Poly(I:C) is a synthetic dsRNA analog and a TLR3 receptor agonist; kanamycin is an antibiotic that stabilizes poly(I:C). It is used in cell culture and in vivo to simulate viral infection and to study immune responses, antimicrobial resistance, and antiviral therapies.
|
| Related CAS # |
Polyinosinic-polycytidylic acid;24939-03-5
|
|---|---|
| Appearance |
Solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~50 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 20 mg/mL (Infinity mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).
(Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
